Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06179602Recruiting
Study of thermal ablation for liver tumors
This study follows patients who are having a procedure called thermal ablation to treat liver tumors. It aims to learn more about how well the procedure works and how safe it is.
LeidenAges 18–110 - NCT06184152Recruiting
Comparing two scans to find liver cancer early
This trial compares two types of imaging scans (CEUS and AMRI) to see which one is better at finding liver cancer (HCC) in patients who have an unclear spot on their liver (an indeterminate nodule). It is for people with cirrhosis who have at least one such nodule but no confirmed liver cancer yet.
Ann Arbor, MichiganAges 18 years+ - NCT06190665Recruiting
Bead type comparison for liver cancer TACE
This trial compares two types of tiny beads used in a liver cancer treatment called TACE to see which works better. If you have liver cancer that needs TACE and your liver is still working fairly well, you may be able to join.
Beijing, Beijing MunicipalityAges 18–80 - NCT06198296RecruitingPhase 1
Armored CAR T cells for GPC3-positive solid tumors
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Houston, TexasAges Up to 21 years - NCT06204835RecruitingPhase 1
ITGA6-targeted dye for liver cancer surgery guidance
This trial uses a special dye that lights up during surgery to help doctors see and remove liver cancer cells that have a specific protein (ITGA6). It aims to make surgery more precise and effective.
Guangzhou, GuangdongAges 18–80 - NCT06205472RecruitingPhase 2
Radiation after liver cancer surgery with narrow margins
This trial tests whether adding a type of radiation (SIB radiotherapy) after liver cancer surgery can improve outcomes for patients whose tumors were removed with very narrow clear margins (less than 1 cm). It may help reduce the chance of cancer coming back in the remaining liver.
BeijingAges 18 years+ - NCT06236568Recruiting
Liver transplant study for liver cancer patients
This study tests a special way to preserve donated livers before transplant to see if it reduces the chance of liver cancer coming back after surgery.
Modena, MOAges 18 years+ - NCT06248580Recruiting
Finding HDV in Turkey Study
This trial is looking for adults in Turkey who have had a hepatitis B infection (HBsAg positive) for at least 6 months. The goal is to see if they also have a hepatitis D virus (HDV) infection. This may help doctors better understand and treat these infections.
AnkaraAges 18 years+ - NCT06294548RecruitingPhase 1/Phase 2
Valemetostat plus atezolizumab and bevacizumab for advanced liver cancer
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
Birmingham, AlabamaAges 18 years+ - NCT05199259Recruiting
Blood test study for people at risk for or with liver cancer
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
Escondido, CaliforniaAges 18 years+ - NCT06327269RecruitingEarly Phase 1
Targeted therapy after liver transplant for high-risk liver cancer
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
Kaohsiung CityAges 18–75 - NCT06345508Recruiting
Finding liver cancer early with ultrasound
This study tests a new ultrasound technique to catch liver cancer sooner. If you have regular imaging checks for liver cancer or are getting an MRI for a liver spot, you may be able to join.
Montreal, QuebecAges 18 years+ - NCT06349317RecruitingPhase 2
Radiation, immunotherapy, and targeted therapy before surgery for liver cancer with portal vein tumor thrombus
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
Fuzhou, FujianAges 18–75 - NCT06383520RecruitingEarly Phase 1
PET imaging for GPC3 in liver cancer
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
Wuhan, HubeiAges 18–65 - NCT06389422RecruitingPhase 2
Radiation plus Keytruda for liver cancer with vein clots
This trial tests a combination of moderate-dose radiation therapy and the immunotherapy drug pembrolizumab (Keytruda) for liver cancer that has spread into the main veins of the liver. It aims to see if this combination can shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–90 - NCT06397222RecruitingPhase 2
Combination therapy for advanced liver cancer
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06397235RecruitingPhase 2
Combination therapy for large liver cancer tumors
This trial tests whether a combination of two treatments—chemoembolization (DEB-TACE) plus chemotherapy given through the liver artery (RALOX-HAIC)—works better than chemoembolization alone for people with large liver cancer tumors (over 7 cm). The goal is to see if the combination shrinks tumors more effectively.
Guangzhou, GuangdongAges 18–75 - NCT06418165Recruiting
Cooled oxygenated machine perfusion for liver transplant
This study tests a new way to preserve donated livers using a machine that keeps the organ cool and oxygenated before transplant. It may help improve how well the liver works after the surgery.
ViennaAges 18 years+ - NCT06418659RecruitingEarly Phase 1
CD-801 for advanced liver cancer
This early-phase trial tests an experimental drug called CD-801 given through an IV for people with advanced liver cancer (HCC) that cannot be surgically removed and has not responded to or is not suitable for standard treatments. The goal is to see if CD-801 is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06434753RecruitingPhase 3
Zinc supplements for stable advanced liver disease
This trial tests whether taking zinc supplements can improve the outlook for people with a certain type of advanced liver disease that is still stable (no major complications). If you have compensated advanced chronic liver disease and meet the criteria, you might be able to join.
BarcelonaAges 18–80 - NCT06454578RecruitingPhase 2
Study of adebrelimab plus apatinib after liver cancer surgery
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Jinan, ShandongAges 18 years+ - NCT06467799RecruitingPhase 2
New drug combo before and after surgery for high-risk liver cancer
This trial tests giving a liver-directed chemotherapy (HAIC) plus an immunotherapy (PD-1) before surgery, followed by more immunotherapy after surgery, for people with a specific type of liver cancer that has a high chance of coming back. The goal is to see if this approach can reduce the risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06478693RecruitingPhase 1
Study of MT-303 for advanced liver cancer
This study tests a new drug called MT-303 for people with advanced liver cancer (HCC) or other cancers that produce a protein called GPC3. The drug is designed to target and attack the cancer cells. The trial is in an early phase, so it is looking at safety and how well the drug works.
Sydney, New South WalesAges 18 years+ - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 589 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.